1. Generics Bulletin
  2. >>Business
  3. >>Deals

Olon Expands With GTP Acquisition

Italian Ingredients Producer Snaps Up French Biotech CDMO

 
• By Dave Wallace

Italy’s Olon Group has acquired French biotech contract development and manufacturing organization GTP Bioways, in a move that Olon says will allow it to “expand and diversify its technological offerings.”

Paolo Tubertini
Olon CEO Paolo Tubertini • Source: Olon

Italian active pharmaceutical ingredients specialist Olon Group has struck a deal to acquire French biotech contract development and manufacturing organization GTP Bioways, in a move that Olon says will allow it to “expand and diversify its technological offerings.”

GTP Bioways specializes in R&D Services, process development and production of monoclonal antibodies, enzymes, proteins, nanodrugs, antibody-drug conjugates and fill-finish....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Sandoz Strikes $300m Deal With Just-Evotec For French Biosimilars Site

 
• By Dave Wallace

Sandoz has made yet another major move to further bolster its booming biosimilars business, striking a $300m deal to acquire outright a French development and manufacturing facility from existing biosimilars partner Just-Evotec Biologics.

Generics Bulletin’s Top 50 Ranking For 2025

 
• By Dave Wallace

This article compiles all of the data from Generics Bulletin’s 2025 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.

Celltrion Nears Deal For US Biologics Plant To Quell Tariff Concerns

 
• By Dean Rudge

Celltrion is the preferred bidder for the acquisition of a large-scale cGMP biologics manufacturing plant in the US, marking a pivotal move to localize production and secure its US pharmaceutical business against rising tariff risks.